FDA-cleared profile

CogNet QmTRIAGE

MedCognetics, Inc. · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.

Clinical role
Passive, prioritization-only, parallel-workflow notification tool: analyzes 2D FFDM screening mammograms and sends an exam-level flag to PACS/workstation for worklist prioritization; it provides no diagnostic information beyond triage and does not remove images from the worklist.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Not diagnostic or a substitute for full evaluation; DBT images and 2D synthetic views are excluded; exact broader device compatibility is unknown.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Complete 2D FFDM screening mammography exams acquired on validated FFDM systems.
  • Who uses it?Intended users: MQSA-qualified interpreting physicians.
  • What does the software produce?Output: Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.
  • What is its most important limitation?Key limitation: Not diagnostic or a substitute for full evaluation; DBT images and 2D synthetic views are excluded; exact broader device compatibility is unknown.

Clinical takeaway. Clinical role: Passive exam-level notification and prioritization of suspicious findings in screening mammograms.

Evidence takeaway. Evidence from the reviewed source record: FDA packet reports 800 retrospective anonymized 2D FFDM exams, 399 biopsy-proven cancer and 401 negative BI-RADS 1/2 cases; AUROC 0.9569 (95% CI 0.9364-0.9738), sensitivity 87%, and specificity 89%. Accuracy 95.6% is not reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Passive exam-level notification and prioritization of suspicious findings in screening mammograms.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Passive, prioritization-only, parallel-workflow notification tool: analyzes 2D FFDM screening mammograms and sends an exam-level flag to PACS/workstation for worklist prioritization; it provides no diagnostic information beyond triage and does not remove images from the worklist.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "is a passive notification for prioritization-only, parallel-workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. QmTRIAGETM utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms" … "produces an exam level output to a PACS/Workstation for flagging the suspicious study and allows for worklist prioritization.". Read from the exact FDA decision document on 2026-11-14.

Required input
Complete 2D FFDM screening mammography exams acquired on validated FFDM systems.
  • Exact FDA submission
  • Checked 2026-09-19

FDA indications statement.

Output and clinician action
Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.
  • Exact FDA submission
  • Checked 2026-09-19

FDA intended-use and technological-characteristics scope.

Care setting
Patients with 2D FFDM screening mammograms (complete exams acquired using validated FFDM systems) in the medical care environment; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment." … "QmTRIAGE™ utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of". Read from the exact FDA decision document on 2026-11-14.

Intended users
MQSA-qualified interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-19

FDA indications statement.

Limitations
Not diagnostic or a substitute for full evaluation; DBT images and 2D synthetic views are excluded; exact broader device compatibility is unknown.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA limitation boundary.

Evidence summary
FDA packet reports 800 retrospective anonymized 2D FFDM exams, 399 biopsy-proven cancer and 401 negative BI-RADS 1/2 cases; AUROC 0.9569 (95% CI 0.9364-0.9738), sensitivity 87%, and specificity 89%. Accuracy 95.6% is not reported.
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported retrospective validation; no subgroup breakdown.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet reports 800 retrospective anonymized 2D FFDM exams, 399 biopsy-proven cancer and 401 negative BI-RADS 1/2 cases; AUROC 0.9569 (95% CI 0.9364-0.9738), sensitivity 87%, and specificity 89%. Accuracy 95.6% is not reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported retrospective validation; no subgroup breakdown.

Reported sensitivity
87%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
89%
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

CogNet QmTRIAGE regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K220080
  • Samplen=800
  • IndependenceIndependence not established

K220080

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K220080. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Complete 2D FFDM screening mammography exams acquired on validated FFDM systems.

    Scope: Exact FDA submission. FDA indications statement.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K220080: CogNet QmTRIAGE

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · CogNet QmTRIAGE model card (K220080)

  3. AI processing

    Source context, not route validation: The exact FDA package describes QmTRIAGE as offering cloud-based analysis, noting that only the predicate also offers an on-premise option. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "While both the proposed device and the predicate offer cloud-based analysis, the predicate also offers an on-premise option.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K220080: CogNet QmTRIAGE

  4. Returned objects

    Source context, not route validation: Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.

    Scope: Exact FDA submission. FDA intended-use and technological-characteristics scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K220080: CogNet QmTRIAGE

  5. Viewer/worklist/report

    Unresolved route: Exam-level PACS/workstation flagging for worklist prioritization; no diagnostic information and no image removal.

    Scope: Exact FDA submission. FDA intended-use and technological-characteristics scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K220080: CogNet QmTRIAGE

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes QmTRIAGE as offering cloud-based analysis, noting that only the predicate also offers an on-premise option. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "While both the proposed device and the predicate offer cloud-based analysis, the predicate also offers an on-premise option.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for CogNet QmTRIAGE; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220080
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Controlled catalog bucket retained; exact FDA scope is 2D FFDM screening mammography, excluding DBT and 2D synthetic views.

Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA comparison-table body part.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-09-29
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K220080 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K220080: CogNet QmTRIAGE

    U.S. Food and Drug Administration - Published 2022-09-29 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. CogNet QmTRIAGE model card (K220080)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K220080

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K220080 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K252482

CogNet AI-MT+

Medcognetics, Inc.

Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2025-12-11
FDA-cleared K233108

VinDr-Mammo

VinBigData Joint Stock Company

The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2024-05-23
FDA-cleared K203517

Saige-Q

DeepHealth, Inc.

Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2021-04-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history